PRIMARY ENEROPATHY-ASSOCIATED T-CELL EXTRNODAL LYMPHOMA DEBUTING WITH COMPLICATIONS. ANALYSIS OF TWO CASE REPORTS AND THE REASONS FOR THEIR UNFAVORABLE OUTCOME
https://doi.org/10.21294/1814-4861-2021-20-2-141-148
Abstract
Background. T-cell lymphoma with small and/or large bowel perforation is classified as a rare and extremely aggressive malignant non-Hodgkin’s lymphoma (NHL). There are two types of T-cell lymphomas: enteropathyassociated T-cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). The most common site of involvement is the small intestine.
Case presentation. A 63-year-old woman and a 50-year-old woman presented with a rare form of primary peripheral T-cell extranodal enteropathy-associated lymphoma (EATL) positive for Cd20 and Cd30. postoperative histological and immunohistochemical examinations of the small intestine resection specimens revealed intestinal perforation.
Conclusion. The delay in diagnosis, multiple lesions, complications, and the rapid disease progression ultimately led to the death of the patients.
About the Authors
A. Z. Almyashev
N.P. Ogarev Mordovia State University
Russian Federation
Russian Federation
MD, PhD, Assistant Professor, Head of Oncology Department
26, Ulyanov Street, Saransk, 430032, Republic of Mordovia, Russia
R. A. Ulyankina
N.P. Ogarev Mordovia State University
Russian Federation
Russian Federation
MD, Oncology Department
26, Ulyanov Street, Saransk, 430032, Republic of Mordovia, Russia
P. I. Skopin
N.P. Ogarev Mordovia State University
Russian Federation
Russian Federation
MD, DSc, Professor of the Oncology Department
26, Ulyanov Street, Saransk, 430032, Republic of Mordovia, Russia
A. A. Ivashin
N.P. Ogarev Mordovia State University
Russian Federation
Russian Federation
MD, Oncology Department
26, Ulyanov Street, Saransk, 430032, Republic of Mordovia, Russia
A. A. Mokhammed
N.P. Ogarev Mordovia State University
Russian Federation
Russian Federation
MD, Oncology Department
26, Ulyanov Street, Saransk, 430032, Republic of Mordovia, Russia
References
1. Felipe-Silva A., de Campos F.P.F., de Medeiros R.S.S., Lourenção R.M., Zerbini M.C.N. Enteropathy-associated T-cell lymphoma (type II): a Brazilian case report. Autops Case Rep. 2012; 2(2): 31–36. doi: 10.4322/acr.2012.014.
2. Zhang J.C., Wang Y., Wang X.F., Zhang F.X. Type I enteropathyassociated T-cell lymphoma in the colon of a 29- year-old patient and a brief literature review. Onco Targets Ther. 2016 Feb; 9: 863–8. doi: 10.2147/OTT.S96745.
3. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Moscow, 2018. 324 p. (in Russian).
4. Sieniawski M.K., Lennard A.L. Enteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies. Curr Hematol Malig Rep. 2011 Dec; 6(4): 231–40. doi: 10.1007/s11899-011-0097-7.
5. Vinogradova Yu.N., Chumachenko A.I., Ryabchikova V.V., Karyagina E.V., Medvedeva N.V., Khodzhibekova M.M., Orlova R.V., Ilyin N.V. Optimization of organ-preserving treatment of patients with extranodal diffuse large B-cell lymphoma of the stomach. Malignant tumors. 2019; 9 (3s1): 3–8. (in Russian).
6. Verbeek W.H., Van De Water J.M., Al-Toma A., Oudejans J.J., Mulder C.J., Coupé V.M. Incidence of enteropathy--associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands. Scand J Gastroenterol. 2008; 43(11): 1322–8. doi: 10.1080/00365520802240222.
7. Al-Toma A., Verbeek W.H., Hadithi M., von Blomberg B.M., Mulder C.J. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut. 2007 Oct; 56(10): 1373–8. doi: 10.1136/gut.2006.114512.
8. Gallamini A., Zaja F., Patti C., Billio A., Specchia M.R., Tucci A., Levis A., Manna A., Secondo V., Rigacci L., Pinto A., Iannitto E., Zoli V., Torchio P., Pileri S., Tarella C. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007 Oct 1; 110(7): 2316–23. doi: 10.1182/blood-2007-02-074641.
9. Soldini D., Mora O., Cavalli F., Zucca E., Mazzucchelli L. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma. Br J Haematol. 2008 Jul; 142(3): 484–6. doi: 10.1111/j.1365-2141.2008.07202.x.
10. Rohatiner A., d’Amore F., Coiffier B., Crowther D., Gospodarowicz M., Isaacson P., Lister T.A., Norton A., Salem P., Shipp M. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994 May; 5(5): 397–400. doi: 10.1093/oxfordjournals.annonc.a058869.
Review
For citations:
Almyashev A.Z., Ulyankina R.A., Skopin P.I., Ivashin A.A., Mokhammed A.A. PRIMARY ENEROPATHY-ASSOCIATED T-CELL EXTRNODAL LYMPHOMA DEBUTING WITH COMPLICATIONS. ANALYSIS OF TWO CASE REPORTS AND THE REASONS FOR THEIR UNFAVORABLE OUTCOME. Siberian journal of oncology. 2021;20(2):141-148. (In Russ.) https://doi.org/10.21294/1814-4861-2021-20-2-141-148
Views:
1186
Email this article 
